An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma

Trial Profile

An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2013

At a glance

  • Drugs Ipilimumab (Primary) ; MDX 1379 (Primary) ; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top